Several recent landmark trials have demonstrated that treatment with sodium–glucose cotransporter 2 inhibitors (SGLT2i) confers significant benefits to patients with heart failure (HF) and/or type 2 diabetes (T2D), resulting in a substantial reduction in adverse cardiovascular events [1]. However, the mechanisms underlying these benefits remain incompletely elucidated [1]. A commonly shared characteristic of individuals with T2D and HF is the elevated cardiac filling pressures [2]. Evidence indicates, that elevated values of pulmonary arterial wedge pressure (PAWP) are associated with impairments in exercise capacity [3] as well as increased risk of morbidity and mortality [4].
